A case of pulmonary adenocarcinoma showing rapid progression of peritoneal dissemination after immune checkpoint inhibitor therapy

Taro Shinozaki, Eri Iwami, Shinnosuke Ikemura, Tatsu Matsuzaki, Takahiro Nakajima, Kazuhiko Hashimoto, Takeshi Terashima

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Immune checkpoint inhibitors are standard treatments for non-small cell lung cancer. Unique cases with paradoxical acceleration of the disease after immunotherapy have been reported. These have been described as cases of hyperprogressive disease. Case presentation: A 76-year-old man was diagnosed with pulmonary adenocarcinoma with pleural dissemination and liver and adrenal metastases. Genomic analysis revealed neither EGFR mutations nor ALK translocations. Immunohistochemical analysis revealed a programmed death-ligand 1 tumor proportion score of 23%. Chemotherapy with carboplatin, paclitaxel, and bevacizumab resulted in Grade 3 skin eruption and disease progression. Pembrolizumab was initiated as a second-line treatment. However, peritoneal dissemination and ascites developed. The patient died 2weeks later. The autopsy revealed widespread peritoneal dissemination and an extensive hemorrhagic infarction. Conclusion: This was a rare case of hyperprogressive disease with rapid progression of peritoneal dissemination after pembrolizumab treatment.

Original languageEnglish
Article number620
JournalBMC Cancer
Volume18
Issue number1
DOIs
Publication statusPublished - 2018 May 31
Externally publishedYes

Fingerprint

Carboplatin
Paclitaxel
Skin Diseases
Ascites
Non-Small Cell Lung Carcinoma
Immunotherapy
Infarction
Disease Progression
Autopsy
Therapeutics
Neoplasm Metastasis
Ligands
Drug Therapy
Mutation
Liver
Adenocarcinoma of lung
Neoplasms
pembrolizumab
Bevacizumab

Keywords

  • Adenocarcinoma
  • Hyperprogressive disease
  • Immune checkpoint inhibitor
  • Lung cancer
  • Pembrolizumab
  • Peritoneal dissemination

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

Cite this

A case of pulmonary adenocarcinoma showing rapid progression of peritoneal dissemination after immune checkpoint inhibitor therapy. / Shinozaki, Taro; Iwami, Eri; Ikemura, Shinnosuke; Matsuzaki, Tatsu; Nakajima, Takahiro; Hashimoto, Kazuhiko; Terashima, Takeshi.

In: BMC Cancer, Vol. 18, No. 1, 620, 31.05.2018.

Research output: Contribution to journalArticle

Shinozaki, Taro ; Iwami, Eri ; Ikemura, Shinnosuke ; Matsuzaki, Tatsu ; Nakajima, Takahiro ; Hashimoto, Kazuhiko ; Terashima, Takeshi. / A case of pulmonary adenocarcinoma showing rapid progression of peritoneal dissemination after immune checkpoint inhibitor therapy. In: BMC Cancer. 2018 ; Vol. 18, No. 1.
@article{0e2d58e72c8f40118b4aaa60cb96f47d,
title = "A case of pulmonary adenocarcinoma showing rapid progression of peritoneal dissemination after immune checkpoint inhibitor therapy",
abstract = "Background: Immune checkpoint inhibitors are standard treatments for non-small cell lung cancer. Unique cases with paradoxical acceleration of the disease after immunotherapy have been reported. These have been described as cases of hyperprogressive disease. Case presentation: A 76-year-old man was diagnosed with pulmonary adenocarcinoma with pleural dissemination and liver and adrenal metastases. Genomic analysis revealed neither EGFR mutations nor ALK translocations. Immunohistochemical analysis revealed a programmed death-ligand 1 tumor proportion score of 23{\%}. Chemotherapy with carboplatin, paclitaxel, and bevacizumab resulted in Grade 3 skin eruption and disease progression. Pembrolizumab was initiated as a second-line treatment. However, peritoneal dissemination and ascites developed. The patient died 2weeks later. The autopsy revealed widespread peritoneal dissemination and an extensive hemorrhagic infarction. Conclusion: This was a rare case of hyperprogressive disease with rapid progression of peritoneal dissemination after pembrolizumab treatment.",
keywords = "Adenocarcinoma, Hyperprogressive disease, Immune checkpoint inhibitor, Lung cancer, Pembrolizumab, Peritoneal dissemination",
author = "Taro Shinozaki and Eri Iwami and Shinnosuke Ikemura and Tatsu Matsuzaki and Takahiro Nakajima and Kazuhiko Hashimoto and Takeshi Terashima",
year = "2018",
month = "5",
day = "31",
doi = "10.1186/s12885-018-4549-5",
language = "English",
volume = "18",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - A case of pulmonary adenocarcinoma showing rapid progression of peritoneal dissemination after immune checkpoint inhibitor therapy

AU - Shinozaki, Taro

AU - Iwami, Eri

AU - Ikemura, Shinnosuke

AU - Matsuzaki, Tatsu

AU - Nakajima, Takahiro

AU - Hashimoto, Kazuhiko

AU - Terashima, Takeshi

PY - 2018/5/31

Y1 - 2018/5/31

N2 - Background: Immune checkpoint inhibitors are standard treatments for non-small cell lung cancer. Unique cases with paradoxical acceleration of the disease after immunotherapy have been reported. These have been described as cases of hyperprogressive disease. Case presentation: A 76-year-old man was diagnosed with pulmonary adenocarcinoma with pleural dissemination and liver and adrenal metastases. Genomic analysis revealed neither EGFR mutations nor ALK translocations. Immunohistochemical analysis revealed a programmed death-ligand 1 tumor proportion score of 23%. Chemotherapy with carboplatin, paclitaxel, and bevacizumab resulted in Grade 3 skin eruption and disease progression. Pembrolizumab was initiated as a second-line treatment. However, peritoneal dissemination and ascites developed. The patient died 2weeks later. The autopsy revealed widespread peritoneal dissemination and an extensive hemorrhagic infarction. Conclusion: This was a rare case of hyperprogressive disease with rapid progression of peritoneal dissemination after pembrolizumab treatment.

AB - Background: Immune checkpoint inhibitors are standard treatments for non-small cell lung cancer. Unique cases with paradoxical acceleration of the disease after immunotherapy have been reported. These have been described as cases of hyperprogressive disease. Case presentation: A 76-year-old man was diagnosed with pulmonary adenocarcinoma with pleural dissemination and liver and adrenal metastases. Genomic analysis revealed neither EGFR mutations nor ALK translocations. Immunohistochemical analysis revealed a programmed death-ligand 1 tumor proportion score of 23%. Chemotherapy with carboplatin, paclitaxel, and bevacizumab resulted in Grade 3 skin eruption and disease progression. Pembrolizumab was initiated as a second-line treatment. However, peritoneal dissemination and ascites developed. The patient died 2weeks later. The autopsy revealed widespread peritoneal dissemination and an extensive hemorrhagic infarction. Conclusion: This was a rare case of hyperprogressive disease with rapid progression of peritoneal dissemination after pembrolizumab treatment.

KW - Adenocarcinoma

KW - Hyperprogressive disease

KW - Immune checkpoint inhibitor

KW - Lung cancer

KW - Pembrolizumab

KW - Peritoneal dissemination

UR - http://www.scopus.com/inward/record.url?scp=85047913347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047913347&partnerID=8YFLogxK

U2 - 10.1186/s12885-018-4549-5

DO - 10.1186/s12885-018-4549-5

M3 - Article

C2 - 29855288

AN - SCOPUS:85047913347

VL - 18

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 620

ER -